DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
69.23
+1.84 (2.73%)
Apr 15, 2025, 4:00 PM EDT - Market closed
DexCom Revenue
In the year 2024, DexCom had annual revenue of $4.03B with 11.34% growth. DexCom had revenue of $1.11B in the quarter ending December 31, 2024, with 7.64% growth.
Revenue (ttm)
$4.03B
Revenue Growth
+11.34%
P/S Ratio
6.76
Revenue / Employee
$391,553
Employees
10,300
Market Cap
27.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| McKesson | 344.58B |
| HCA Healthcare | 70.60B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Sanofi | 45.85B |
| Thermo Fisher Scientific | 42.88B |
| GSK plc | 39.28B |
| Medtronic | 33.20B |
DXCM News
- 5 days ago - FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
- 5 days ago - DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance - Barrons
- 5 days ago - Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Business Wire
- 12 days ago - Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time. - Business Wire
- 14 days ago - Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems - Business Wire
- 15 days ago - These 20 worst-performing stocks in the S&P 500 sank 17% or more in March - Market Watch
- 21 days ago - Dexcom Appoints Jon Coleman as Chief Commercial Officer - Business Wire
- 21 days ago - Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom - Business Wire